Related Experiment Video
Updated: Jun 26, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 10, 2014
Therapeutic interventions for HIV infection and chronic viral hepatitis
1Division of Infectious Diseases, The Ottawa Hospital-General Campus, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Ccooper@ottawahospital.on.ca
Abstract:
Combination antiretroviral therapy reduces overall and liver-specific morbidity and mortality in coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) and represents the most beneficial pharmaceutical treatment intervention for most coinfected patients. Antiviral therapy for HCV infection is potentially organ- and life-saving but, in general, should be reserved for patients who achieve suppression of HIV RNA and immune restoration from combination antiretroviral therapy or for patients with nadir CD4+ T lymphocyte levels of >350 cells/microL. Safe and virologically active treatment of coinfection with HIV and hepatitis B virus can be concurrently achieved by the use of combination antiretroviral therapy regimens containing lamivudine and/or tenofovir.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Inhibitors of Virion Maturation and Assembly

